drugset / Trial / NCT00977145

Evaluating the Safety and the Biological Effects of Intratumoral Interferon Gamma and a Peptide-Based Vaccine in Patients With Melanoma

NCT00977145

Phase 1 Terminated 11 enrolled Craig L Slingluff, Jr
NaSingle-groupOpen-labelTreatment

Summary

The goals of this study are to evaluate 1) the safety of administration of intratumoral interferon gamma with a peptide-based vaccine, in patients with melanoma and 2) the biological effects of the vaccine. These include an examination of changes within the tumor following vaccination and the evaluation of T cell responses to the vaccine both in the blood and at the sight of tumor.

Timeline

Start
2009-11
Primary completion
2012-10
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject MELITAC 12.1 Vaccine 100 ug Subcutaneous
Subject MELITAC 12.1 Vaccine 200 ug Subcutaneous
Subject interferon gamma Protein / enzyme biologic 2e+06 iu Other

Indications